Hematology

Cardio-Oncology

Questions discussed in this category

For CLL patients with high-risk cytogenetics on ibrutinib who develop a cardiac event such as an MI, would you continue ibrutinib?

Would you continue ibrutinib even if they are placed on anti-platelet therapy such as clopidogrel or ticagrelor? When do you switch to an altern...

5 Answers available

What are your management strategies for malignant pericardial effusion with a high risk of spontaneous hemorrhage, particularly in patients requiring anticoagulation for chronic atrial fibrillation?

1 Answer available

How do you manage severe hypertriglyceridemia in the adolescent & young adult population receiving chemotherapy for ALL, in the absence of complications related to hypertriglyceridemia?

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2015-12-17

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Blood, 2022 Jul 14

Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.

Leukemia, 2021 Apr 27

Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies.

J Am Coll Cardiol, 2019 Oct 01

Cardiovascular Toxicities Associated With Ibrutinib.

Related Topics in Hematology